ArticleEuropean urology2024

Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.

Carlos Toribio-Vázquez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.